Literature DB >> 10874387

Uncertainty of incremental cost-effectiveness ratios. A comparison of Fieller and bootstrap confidence intervals.

J L Severens1, T M De Boo, E M Konst.   

Abstract

OBJECTIVE: To compare different methods to estimate the confidence interval of the incremental cost-effectiveness ratio (ICER).
METHODS: The adequacy of Fieller intervals and three methods for calculating bootstrap intervals are compared based on a simulation of 10,000 trials, using data from one trial.
RESULTS: Both Fieller and bootstrap methods lead to unsatisfactory results when the difference in effectiveness is approximately zero. Where this difference is significant, the four methods for calculating confidence intervals for ICER do not give very different results, but Fieller's interval performs best.
CONCLUSIONS: Since Fieller's confidence limits are relatively easy to compute compared with bootstrap simulations, we recommend using this method.

Mesh:

Year:  1999        PMID: 10874387

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  11 in total

Review 1.  Sample size determination for cost-effectiveness trials.

Authors:  Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

2.  Cost-effectiveness of open versus laparoscopic appendectomy: a multilevel approach with propensity score matching.

Authors:  Laura Haas; Tom Stargardt; Jonas Schreyoegg
Journal:  Eur J Health Econ       Date:  2011-10-08

3.  Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis.

Authors:  A Boonen; D van der Heijde; J L Severens; A Boendermaker; R Landewé; J Braun; J Brandt; J Sieper; Sj van der Linden
Journal:  Ann Rheum Dis       Date:  2005-07-13       Impact factor: 19.103

Review 4.  Cost-effectiveness acceptability curves and a reluctance to lose.

Authors:  Johan L Severens; Daniëlle E M Brunenberg; Elisabeth A L Fenwick; Bernie O'Brien; Manuela A Joore
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

5.  Cost-Effectiveness of Antibody-Based Induction Therapy in Deceased Donor Kidney Transplantation in the United States.

Authors:  Zahra Gharibi; Mehmet U S Ayvaci; Michael Hahsler; Tracy Giacoma; Robert S Gaston; Bekir Tanriover
Journal:  Transplantation       Date:  2017-06       Impact factor: 4.939

6.  Reablement in community-dwelling older adults: a cost-effectiveness analysis alongside a randomized controlled trial.

Authors:  Egil Kjerstad; Hanne Kristin Tuntland
Journal:  Health Econ Rev       Date:  2016-05-10

7.  Cost-effectiveness of e-cigarettes compared with nicotine replacement therapy in stop smoking services in England (TEC study): a randomized controlled trial.

Authors:  Jinshuo Li; Peter Hajek; Francesca Pesola; Qi Wu; Anna Phillips-Waller; Dunja Przulj; Katie Myers Smith; Natalie Bisal; Peter Sasieni; Lynne Dawkins; Louise Ross; Maciej Lukasz Goniewicz; Hayden McRobbie; Steve Parrott
Journal:  Addiction       Date:  2019-12-04       Impact factor: 6.526

8.  Cost-effectiveness of a complex intervention to reduce children's exposure to second-hand smoke in the home.

Authors:  Charlotte Renwick; Qi Wu; Magdalena Opazo Breton; Rebecca Thorley; John Britton; Sarah Lewis; Elena Ratschen; Steve Parrott
Journal:  BMC Public Health       Date:  2018-11-13       Impact factor: 3.295

9.  Cost-Effectiveness of a Web-Based Program for Residual Depressive Symptoms: Mindful Mood Balance.

Authors:  Jennifer M Boggs; Debra P Ritzwoller; Arne Beck; Sona Dimidjian; Zindel V Segal
Journal:  Psychiatr Serv       Date:  2021-07-29       Impact factor: 3.084

10.  Cost-effectiveness of personal tailored risk information and taster sessions to increase the uptake of the NHS stop smoking services: the Start2quit randomized controlled trial.

Authors:  Qi Wu; Hazel Gilbert; Irwin Nazareth; Stephen Sutton; Richard Morris; Irene Petersen; Simon Galton; Steve Parrott
Journal:  Addiction       Date:  2017-12-11       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.